• Company
• Release of triple-combo diabetes drugs imminent
• by Kim, Jin-Gu Jul 7, 2023 05:43am

• Policy
• Taiwanese new drug receives reimb in only 1 yr since release
• by Lee, Tak-Sun Jul 7, 2023 05:43am

• Company
• Baxter and Fresenius Medical benefited the most
• by Nho, Byung Chul Jul 7, 2023 05:43am

• Policy
• Evaluation different after Kymriah·Zolgensma benefits?
• by Lee, Tak-Sun Jul 7, 2023 05:43am

• Policy
• Pres. Yoon urges swift legislation for remote treatment
• by Kang, Shin-Kook Jul 6, 2023 05:39am

• Company
• Vabysmo’s real-world data to hold leader Eylea in check
• by Jung, Sae-Im Jul 6, 2023 05:39am

• Policy
• Roche Korea, "No decision has been made to resupply Madopar
• by Lee, Tak-Sun Jul 6, 2023 05:39am

• Company
• Industry anxiously awaits reimb of SGLT-2 inhibitors
• by Jung, Sae-Im Jul 6, 2023 05:39am

• Company
• Sidapvia, a combination of Forxiga in collaboration
• by Jung, Sae-Im Jul 6, 2023 05:38am

• Company
• Dongkook and GC agree to co-promote Glarzia in Korea
• by Kim, Jin-Gu Jul 5, 2023 05:45am